Health TrialsbyHealthPanel

Malignant Mesothelioma (MM)

2

Review clinical trials related to Malignant Mesothelioma (MM). Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subjects with BRCA1-Associated Protein-1 (BAP1) Cancer Predisposition Syndrome (CPDS) and subclinical, early-stage mesothelioma. Progression-free survival (PFS) will also be determined for treated subjects, and the treatment safety (toxicity) evaluated....

Participants needed: 15
Trial details
Phase: Phase 2Age: 18-120Biological sex: AllType: InterventionalSponsor: National Cancer Institute (NCI)Updated: Sep 23, 2026Locations: 1
Eligibility criteria

Participants with history of germline BRCA1-Associated Protein-1 (BAP1) mutation... [+22]

Participants with cancers requiring frontline standard of care treatment. [+11]

Read more
Status: Not yet recruiting

Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors

This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors

Participants needed: 219
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: TYK Medicines, IncUpdated: Dec 22, 2025Locations: 1
Eligibility criteria

Male or female subjects ≥18 years old [+7]

Presence of pleural effusion, pericardial effusion, or ascites that, in the inve... [+6]

Read more